Mr. Ian Wilson is the former CEO and CTO of Edinburgh Molecular Imaging Ltd, leading the development of novel optical imaging agents to improve cancer detection and surgery, and lung disease. He has held several roles at GE Healthcare between 1996 and 2013, including Portfolio and Strategy Manager and Head of Biology, with responsibility for management of GE Healthcare’s Molecular Imaging Agent Portfolio, in Cardiovascular, Oncology and Neurology, and strategic and tactical oversight. He had responsibility for supporting efficacy and regulatory studies required for the approval of new imaging agents. At Xstrahl Ltd, as CTO &COO, he was responsible for the oversight of the Radiotherapy commercial operation and manufacture oversight, including new product development. Mr. Wilson currently works and resides in the UK, though he travels extensively on behalf of ImaginAb. He is a graduate from University of Manchester with over 25 years’ experience in development of in vivo medical diagnostics and imaging medical devices.
Thilo Schroeder, PhDDirector
Thilo Schroeder, Ph.D. is Partner at Nextech Invest Ltd., a global venture fund focused on investing in oncology companies. Prior to joining Nextech Invest in 2012, Dr. Schroeder worked in research specializing on the development of Designed Ankyrin Repeat Proteins (DARPins) as specific protein inhibitors. He acquired expertise in molecular biology as an Intern at Micromet Ltd. (now Amgen) and during his studies at the University of Sydney. Dr. Schroeder currently serves as board member of ImaginAb and board observer of Peloton Therapeutics. He is a prior board member of Blueprint Medicines (NASDAQ:BPMC), SiROP Global, and board observer of Tracon Pharmaceuticals (NASDAQ:TCON). He holds a Ph.D. in biochemistry from the University of Zurich in Switzerland, a M.Sc. in biotechnology from the Ecole de Supérieure de Biotechnologie de Strasbourg in France, and a B.Sc. in biology from the Technical University of Darmstadt in Germany.
Friedhelm Blobel, PhDIndependent Non-Executive Director
Friedhelm Blobel, Ph.D., currently serves as board member of private Life Science companies (ImaginAb, ENTvantage, and SciClone Pharmaceuticals International Ltd). From June 2006 until its acquisition by a Chinese consortium in October 2017 he served as President, Chief Executive Officer and a Director for SciClone Pharmaceuticals, Inc. Throughout these years SciClone was a NASDAQ listed company, based in the San Francisco Bay Area with a specialty pharmaceuticals business focused in China, managing its own sales force and recent annual revenues of approximately $150 million. From July 2000 to 2006 Dr. Blobel was President, Chief Executive Officer and a Director of Gryphon Therapeutics, Inc., a private South San Francisco-based biopharmaceutical company. Prior to joining Gryphon Dr. Blobel spent more than two decades as an executive with the Hoechst Group and the Boehringer Mannheim Group, including responsibilities in the areas of diabetes and in vitro diagnostics. For these companies, he lived and worked eight years in Europe and Japan before moving to the USA. Dr. Blobel holds a Ph.D. in Biochemistry and Microbiology from the University of Hohenheim, Germany.
K. Leonard JudsonDirector
K. Leonard Judson is the President and Managing Director of Cycad Group. Prior to co-founding Cycad Group in 2000, he practiced law for 14 years and was a partner in two law firms including May, Potenza, Judson and Baran, P.C. where he served as its CEO until his departure to the Cycad Group. Throughout his legal career a substantial portion of his practice was devoted to representing both entrepreneurs and investors in various aspects corporate law, finance, mergers and acquisitions. Leveraging upon his experience interning for the SEC and his subsequent securities law practice, Leonard was as a member of the NASD Board of Arbitrators from 1989 to 2002 and chaired numerous securities industry related arbitrations. Among his responsibilities at Cycad Group, Leonard currently serves as a Director or observer to the board of directors of several of Cycad Group’s portfolio companies including, ImaginAb, Nanosteel Corporation, Sofie Biosciences, and Lixivia. Leonard is also a Director and the Executive Vice President of the Glenn Foundation For Medical Research, Inc., a non-profit foundation supporting basic research to understand the biology of aging with the objective of developing interventions to extend the healthy years of human life. Leonard holds a J.D. with Honors, from George Washington University, Washington, D.C., and a B.S. degree, Cum Laude, from Northern Arizona University.
Anna M. Wu, PhDFounder and Chief Scientific Advisor
Dr. Anna Wu is a Professor in the Department of Molecular and Medical Pharmacology and a Professor in Pathology and Laboratory Medicine at the David Geffen School of Medicine at UCLA. Previously, Dr. Wu was a Professor of Molecular Biology at the Beckman Research Institute of the City of Hope in Duarte, CA. Dr. Wu is a respected leader in molecular imaging who currently serves as the Director of the Cancer Molecular Imaging Program in the Jonsson Comprehensive Cancer Center at UCLA. She also served as President and is currently a Fellow of the World Molecular Imaging Society. As an acknowledged expert in engineered antibodies for cancer targeting, Dr. Wu’s research is the foundation of ImaginAb’s technology. Dr. Wu received her A.B. in Biochemical Sciences from Harvard University and a PhD in Molecular Biophysics and Biochemistry from Yale University.
Tim IrishIndependent Non-Executive Director
Tim has worked in the life sciences industry for thirty years. His career has spanned global health technology companies across Europe and North America, including GSK, GE and Philips. Between 2007 and 2015 he served on ten Boards, five as Chair, where he successfully executed two trade sales and raised significant equity financing, including an IPO. Since 2015 his current governance portfolio covers Life Sciences and Healthcare, both public and private, including board roles as Senior Independent Director and Non-Executive Director at NICE, four European NED roles, and Professor of Practice at King’s College London’s School of Management and Business.